Table 2.

Multivariate analysis for factors associated with CKD progression

	Model 1 (without biologics use)		Model 2 (with biologics use)
Factor	OR (95% CI)	P-value	OR (95% CI)	P-value
Age at bDMARD initiation	1.05 (0.99–1.06)	.002	1.01 (0.98–1.03)	<.001
Female	1.00 (0.87–1.11)	.342	0.99 (0.88–1.25)	.531
eGFR level at bDMARD initiation	1.01 (0.97–1.04)	.412	1.01 (0.99–1.03)	.411
Mean Hb level	0.89 (0.77–1.60)	.215	1.18 (0.89–1.71)	.254
Mean LDL level	0.98 (0.96–1.02)	.435	0.97 (0.97–1.10)	.546
NSAID use	3.47 (1.01–11.99)	.004	4.11 (1.57–10.74)	.004
Anti-hypertensive drug use	2.42 (0.77–7.76)	.127	2.22 (0.91–5.35)	.077
Mean CRP level >0.14 mg/dL	5.89 (1.43–24.74)	.015	2.23 (0.90–5.48)	.082
Mean CDAI score >5.8	1.11 (0.40–3.35)	.924	1.57 (0.67–3.58)	.359
Tocilizumab use			0.31 (0.11–0.89)	.027
Abatacept use			1.34 (0.45–3.64)	.582